News

Neoadjuvant chemotherapy with nanoparticle albumin-bound nab-paclitaxel has demonstrated substantial activity across major subgroups of breast cancer, a meta-analysis of clinical trials showed.

Denise A. Yardley, MD, discusses the tnAcity clinical trial results and current role of nab-paclitaxel in TNBC, as well as the potential for using nab-paclitaxel in combination with immunotherapy in this setting.

The combination of the Fc-modified monoclonal antibody margetuximab with chemotherapy may offer a new treatment option for patients with HER2-positive metastatic breast cancer.

Targeted therapies and immunotherapy are revolutionizing oncology, however, chemotherapy retains a key role in the treatment of advanced prostate cancer, with recent data showing profound benefits with docetaxel in newly diagnosed patients.

Sarcoma physician and researcher Robert G. Maki, MD, PhD, has joined the leadership team at Northwell Health Cancer Institute.

Arie Perry, MD, chief of neuropathology at UCSF in San Francisco, California, discusses what oncologists should be aware of when diagnosing patients after these reclassifications, how it could change pathology, as well as a discussion on hereditary tumors.

Elizabeth Loggers, MD, PhD, discusses the findings of the phase II SARC028 trial in sarcoma.

The results of a recent randomized study showed anti-HER2 DC1 vaccination to be a safe and immunogenic treatment to induce tumor-specific T-cell responses in patients with HER2-positive breast cancer.

While mutations of the <em>BRCA</em> gene can increase a woman&rsquo;s chances of developing breast and ovarian cancers, the presence of the gene made no difference in survival for women aged 40 years or younger who were diagnosed with early-stage breast cancer.

Claire Verschraegen, MD, discusses the design and findings of an early trial of avelumab and the future potential for the PD-L1 inhibitor in lung cancer.

Maria Ignez Braghiroli, MD, discusses a study that parsed out patients with solely NRAS-mutated colorectal cancer, what the current treatment paradigm is for these patients, and how the mutation status of a patient with colorectal cancer may affect their treatment.

Chung-Han (Joe) Lee, MD, discusses&nbsp;recent treatment approvals in RCC, current and emerging treatments and strategies, and the significance of clinical trial enrollment.

Michael J. Morris, MD, discusses&nbsp;the use of bone-seeking radiopharmaceuticals in prostate cancer, with a specific focus on radium-223.

A supplemental biologics license application for pembrolizumab in combination with pemetrexed plus carboplatin has been granted priority review by the FDA as a treatment for patients with metastatic or advanced non-squamous non&ndash;small cell lung cancer without <em>EGFR</em> or <em>ALK</em> mutations and regardless of PD-L1 expression.

A supplemental new drug application for the PD-L1 inhibitor atezolizumab has been granted priority review by the FDA in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring &ge;12 months after neoadjuvant or adjuvant chemotherapy.

Mark G. Kris, MD,&nbsp;shares his thoughts on the prominent advancements in the field of lung cancer, how liquid biopsies are shaping treatment decisions, and his predictions for the years ahead.

PD-L1 expression is starting to be part of the standard of care in determining the appropriate treatment plan for newly diagnosed non-small cell lung cancer. However, testing for the biomarker is not always necessary for patients who have relapsed or who have small cell lung cancer.

The combination of PEGPH20 with nab-paclitaxel and gemcitabine demonstrated improvements in progression-free survival compared with nab-paclitaxel/gemcitabine alone for untreated patients with advanced pancreatic cancer.

Tanios Bekaii-Saab, MD, discusses&nbsp;questions regarding regorafenib and TAS-102 in mCRC, compares the mechanisms of action and toxicities of both therapies, and shares his views on the optimal sequencing of the 2 agents.

The clinical hold on trials exploring pacritinib has been lifted by the FDA, according to CTI BioPharma, the developer of the JAK2/FLT3 inhibitor.

Cristina Gasparetto, MD, discuss treatment considerations and options for patients with multiple myeloma based on 2 case scenarios.

A supplemental new drug application (sNDA) for the use of regorafenib (Stivarga) as a second-line treatment for patients with unresectable hepatocellular carcinoma (HCC) has been granted priority review by the FDA.

In a recent early-stage HER2-positive breast cancer trial, prophylactic treatment with the combination of loperamide and budesonide reduced the rate of grade 3 diarrhea associated with neratinib to 15%.

Sibylle Loibl, MD, PhD, discusses the most recent subanalysis of the GeparSepto trial, how the drugs match up in terms of toxicities, and a separate set of data looking at patients with breast cancer who are also pregnant.

Julia White, MD, discusses the upcoming phase II trial, the toxicities associated with the treatment, and the potential for control of these metastases. According to White, the trial is still accruing its 143 patients.

The FDA has granted a priority review to a biologics license application for durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Gopa Iyer, MD, discusses the standard chemotherapy options available for patients with bladder cancer, the ongoing progress with immunotherapy, and the management of immune-related toxicities.

Dean Bajorin, MD, discusses the ongoing studies exploring new chemotherapy approaches in these patients and how the cytotoxic treatments could still ultimately be replaced with immuno-oncology agents.

The addition of enzalutamide to abiraterone acetate and prednisone failed to improve progression-free survival versus abiraterone and prednisone alone in chemotherapy-na&iuml;ve patients with metastatic castration-resistant prostate cancer who progressed on enzalutamide.

Paul Kelly Marcom, MD, discusses the future landscape of HR-positive breast cancer, highlighting the influence of CDK4/6 inhibitors and targeted agent/endocrine therapy combinations.